Department of Cosmetic Science, Providence University, 200, Sec. 7, Taiwan Boulevard, Shalu Dist, Taichung, 43301, Taiwan.
School of Pharmacy, National Taiwan University, No.33, Linsen S. Rd., Zhongzheng Dist, Taipei, 100, Taiwan.
Naunyn Schmiedebergs Arch Pharmacol. 2018 Jun;391(6):587-602. doi: 10.1007/s00210-018-1484-6. Epub 2018 Mar 28.
Although the therapeutics have improved the rates of remission and cure of acute myelogenous leukemia (AML) in recent decades, there is still an unmet medical need for AML therapies because disease relapses are a major obstacle in patients who become refractory to salvage therapy. The development of therapeutic agents promoting both cytotoxicity and cell differentiation may provide opportunities to improve the clinical outcome. Dioscin-induced apoptosis in leukemic cells was identified through death receptor-mediated extrinsic apoptosis pathway. The formation of Bak and tBid, and loss of mitochondrial membrane potential were induced by dioscin suggesting the activation of intrinsic apoptotsis pathway. A functional analysis of transcription factors using transcription factor-DNA interaction array and IPA analysis demonstrated that dioscin induced a profound increase of protein expression of CCAAT/enhancer-binding protein α (C/EBPα), a critical factor for myeloid differentiation. Two-dimensional gel electrophoresis assay confirmed the increase of C/EBPα expression. Dioscin-induced differentiation was substantiated by an increase of CD11b protein expression and the induction of differentiation toward myelomonocytic/granulocytic lineages using hematoxylin and eosin staining. Moreover, both glycolysis and gluconeogenesis pathways after two-dimensional gel electrophoresis assay and IPA network enrichment analysis were proposed to dioscin action. In conclusion, the data suggest that dioscin exerts its antileukemic effect through the upregulation of both death ligands and death receptors and a crosstalk activation of mitochondrial apoptosis pathway with the collaboration of tBid and Bak formation. In addition, proteomics approach reveals an altered metabolic signature of dioscin-treated cells and the induction of differentiation of promyelocytes to granulocytes and monocytes in which the C/EBPα plays a key role.
尽管近几十年来治疗方法的改进提高了急性髓细胞白血病 (AML) 的缓解率和治愈率,但 AML 治疗仍存在未满足的医学需求,因为疾病复发是对挽救疗法产生耐药的患者的主要障碍。开发既能促进细胞毒性又能促进细胞分化的治疗药物可能为改善临床结果提供机会。薯蓣皂苷元通过死亡受体介导的外在凋亡途径诱导白血病细胞凋亡。薯蓣皂苷元诱导 Bak 和 tBid 的形成以及线粒体膜电位的丧失提示内在凋亡途径的激活。使用转录因子-DNA 相互作用阵列和 IPA 分析对转录因子进行功能分析表明,薯蓣皂苷元诱导 CCAAT/增强子结合蛋白 α (C/EBPα) 的蛋白表达显著增加,C/EBPα 是髓样分化的关键因子。二维凝胶电泳分析证实了 C/EBPα 表达的增加。薯蓣皂苷元诱导分化的证据是 CD11b 蛋白表达增加,以及使用苏木精和伊红染色诱导向髓单核细胞/粒细胞谱系分化。此外,二维凝胶电泳分析和 IPA 网络富集分析均提出糖酵解和糖异生途径是薯蓣皂苷元的作用机制。总之,数据表明薯蓣皂苷元通过上调死亡配体和死亡受体,并通过 tBid 和 Bak 形成的协作激活线粒体凋亡途径来发挥其抗白血病作用。此外,蛋白质组学方法揭示了薯蓣皂苷元处理细胞的代谢特征发生改变,并诱导早幼粒细胞向粒细胞和单核细胞分化,其中 C/EBPα 发挥关键作用。